Scholars@Duke
Louis Frederic Diehl

Louis Frederic Diehl

Professor Emeritus of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
louis.diehl@duke.edu
DUMC Box 3961, Durham, NC 27710
2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710

Scholarly Works - Conferences

Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma.

Conference Journal of Clinical Oncology · May 20, 2017 8008 Background: The combination of bendamustine, pomalidomide, and dexamethasone (BPd) displays promising activity in heavily pretreated RRMM. In the Phase I portion, MTD was 120 mg/m2bendamustine/3mg pomali ... Full text Cite

A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Conference Blood · December 3, 2015 AbstractBackgroundBendamustine, a bifunctional mechlorethamine derivative with alkylating properties and pomalidomide, an IMiD® immunomodulatory agent, have both demonstrated ... Full text Cite

Atypical Primary Effusion Lymphoma In A Lung Transplant Recipient

Conference AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE · January 1, 2015 Link to item Cite

Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Conference Blood · November 16, 2012 AbstractAbstract 1626Background:Diffuse Large B-cell Lymphoma (DLBCL) patients with primary refractor ... Full text Cite

Pilot Study of Sorafenib for Myelodysplastic Syndrome

Conference Blood · November 16, 2012 AbstractAbstract 4948Background:MDS (Myelodysplastic syndrome) is a hematologic malignancy in which o ... Full text Cite

Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS

Conference Blood · November 16, 2012 AbstractAbstract 4935Background:Myelodysplasticsyndromes (MDS) are a heterogeneous group of hematopoi ... Full text Cite